Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome.
Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome.
复制标题
DOI：
10.1586/erv.12.126
复制
发表时间：
2012-12
影响因子：
6.2
通讯作者：
Hotez PJ
中科院分区：
文献类型：
--
作者：
Jiang S;Bottazzi ME;Du L;Lustigman S;Tseng CT;Curti E;Jones K;Zhan B;Hotez PJ
A subunit vaccine, RBD-S, is under development to prevent severe acute respiratory syndrome (SARS) caused by SARS coronavirus (SARS-CoV), which is classified by the US NIH as a category C pathogen. This vaccine is comprised of a recombinant receptor-binding domain (RBD) of the SARS-CoV spike (S) protein and formulated on alum, together with a synthetic glucopyranosyl lipid A. The vaccine would induce neutralizing antibodies without causing Th2-type immunopathology. Vaccine development is being led by the nonprofit product development partnership; Sabin Vaccine Institute and Texas Children’s Hospital Center for Vaccine Development in collaboration with two academic partners (the New York Blood Center and University of Texas Medical Branch); an industrial partner (Immune Design Corporation); and Walter Reed Army Institute of Research. A roadmap for the product development of the RBD-S SARS vaccine is outlined with a goal to manufacture the vaccine for clinical testing within the next 5 years.
登录
查看更多内容
影响因子：
4.8
作者：
Cao Z;Liu L;Du L;Zhang C;Jiang S;Li T;He Y
通讯作者：
He Y
影响因子：
64.8
作者：
Li W;Moore MJ;Vasilieva N;Sui J;Wong SK;Berne MA;Somasundaran M;Sullivan JL;Luzuriaga K;Greenough TC;Choe H;Farzan M
通讯作者：
Farzan M
DOI：
10.1016/j.bbrc.2009.05.003
发表时间：
2009-07-10
影响因子：
3.1
作者：
Du, Lanying;Zhao, Guangyu;Li, Lin;He, Yuxian;Zhou, Yusen;Zheng, Bo-Jian;Jiang, Shibo
通讯作者：
Jiang, Shibo
影响因子：
--
作者：
Asojo, Oluwatoyin A.;Homma, Kohei;Hotez, Peter J.
通讯作者：
Hotez, Peter J.
影响因子：
2.2
作者：
Du, Lanying;Zhao, Guangyu;Jiang, Shibo
通讯作者：
Jiang, Shibo